Nurix Therapeutics Inc (NRIX)

$18.09 +0.07 (0.39%)
Market Cap 1.39B
Revenue (ttm) 54.55M
Net Income (ttm) -193.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -354.85%
Debt to Equity Ratio 0.00
Volume 1,228,800
Avg Vol 1,649,396
Day's Range N/A - N/A
Shares Out 76.88M
Stochastic %K 87%
Beta 1.87
Analysts Strong Sell
Price Target $26.72

Company Profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BT...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 660 5320
Fax: 415 525 4200
Address:
1700 Owens Street, Suite 205, San Francisco, United States
RonIsWrong
RonIsWrong Dec. 7 at 5:41 AM
$NRIX Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging data from randomized Phase 1b cohorts points to higher ORR and longer progression free survival at the 600 mg recommended Phase 2 dose (RP2D) compared to the 200 mg dose Bexobrutideg was well tolerated with a consistent safety profile between the 600 mg RP2D and the overall study population Phase 2 clinical trial of bexobrutideg (DAYBreak-CLL-201) currently enrolling globally call monday more: https://finance.yahoo.com/news/nurix-therapeutics-presents-data-demonstrating-143000212.html
0 · Reply
justiceforb_85
justiceforb_85 Dec. 7 at 2:15 AM
$NRIX data is good but wondering what the TAM is for relapsed disease? New data out suggesting limited treatment may be feasible in front-line setting.
1 · Reply
oaksapollo
oaksapollo Dec. 6 at 3:26 PM
$NRIX well the update is out, seems pretty much as I expected, but not going to knock anyone’s socks off. I suspect we trade slightly lower Monday? https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-presents-new-data-demonstrating-durable
1 · Reply
LongTrainRunning
LongTrainRunning Dec. 5 at 7:42 PM
$NRIX Looks like the stock is settling in around $18 before ASH. I'm excited to see the ASH data press release, perhaps in a couple hours. Hopefully we start next week off in the 20s. Good luck fellow longs!
1 · Reply
oaksapollo
oaksapollo Dec. 4 at 4:43 PM
$NRIX this is anecdotal but does suggest that maybe bexo data takes time to mature. This patient had a CR after 2 years of treatment!
1 · Reply
oaksapollo
oaksapollo Dec. 4 at 4:28 PM
$NRIX there are not many options trades made for this stock but what little trading does go on seems to indicate the ASH data will be very good. There are bids for even Dec $25 strike calls. We’ll find out Monday.
1 · Reply
degeneratetrader23
degeneratetrader23 Dec. 2 at 4:20 PM
$NRIX whats with the dip?
1 · Reply
Smellmahass
Smellmahass Dec. 1 at 2:32 PM
$NRIX Is this the data on December 8th?
1 · Reply
JFais
JFais Nov. 28 at 10:01 PM
When not seeing much that I like in scans (valuations too rich across sector $XBI) Good reminder to set price alerts for reminders to revisit Most won't get triggered, but the few that do make this practice worth it (by far) Ie. $ARWR at $45, $NRIX at $14, the list goes on..
0 · Reply
JarvisFlow
JarvisFlow Nov. 24 at 6:13 PM
Truist Securities has updated their rating for Nurix Therapeutics ( $NRIX ) to Buy with a price target of 30.
0 · Reply
Latest News on NRIX
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Dec 6, 2025, 9:30 AM EST - 1 day ago

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 1, 2025, 7:00 AM EST - 6 days ago

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 7:00 AM EST - 12 days ago

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

Nov 10, 2025, 7:00 AM EST - 27 days ago

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

Nov 7, 2025, 9:00 AM EST - 4 weeks ago

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Nov 3, 2025, 9:00 AM EST - 4 weeks ago

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Oct 30, 2025, 7:00 AM EDT - 5 weeks ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

Oct 27, 2025, 7:00 AM EDT - 5 weeks ago

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

Nurix Therapeutics, Inc. (NRIX) Discusses Clinical and Preclinical Updates on BTK, STAT6, and IRAK4 Degrader Programs Transcript

Oct 22, 2025, 6:53 PM EDT - 6 weeks ago

Nurix Therapeutics, Inc. (NRIX) Discusses Clinical and Preclinical Updates on BTK, STAT6, and IRAK4 Degrader Programs Transcript

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

Oct 22, 2025, 7:20 AM EDT - 6 weeks ago

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

Oct 22, 2025, 6:00 AM EDT - 6 weeks ago

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

Oct 18, 2025, 3:00 AM EDT - 7 weeks ago

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones

Oct 11, 2025, 8:13 AM EDT - 2 months ago

Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Oct 9, 2025, 4:01 PM EDT - 2 months ago

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Sep 17, 2025, 7:00 AM EDT - 2 months ago

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Nurix Therapeutics, Inc. (NRIX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 12, 2025, 9:56 AM EDT - 3 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Nurix Therapeutics, Inc. (NRIX) Presents At Baird Global Healthcare Conference 2025 (Transcript)

Sep 12, 2025, 9:43 AM EDT - 3 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At Baird Global Healthcare Conference 2025 (Transcript)

Nurix Therapeutics, Inc. (NRIX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 11, 2025, 3:14 AM EDT - 3 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Nurix Therapeutics, Inc. (NRIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 9:42 AM EDT - 3 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors

Jul 13, 2025, 8:30 AM EDT - 5 months ago

Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 9, 2025, 4:01 PM EDT - 5 months ago

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

Jul 7, 2025, 7:00 AM EDT - 5 months ago

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 13, 2025, 4:01 PM EDT - 6 months ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Jun 12, 2025, 7:00 AM EDT - 6 months ago

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Jun 6, 2025, 7:00 AM EDT - 6 months ago

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

Jun 2, 2025, 7:00 AM EDT - 6 months ago

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 7:00 AM EDT - 6 months ago

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 7 months ago

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

May 14, 2025, 9:30 AM EDT - 7 months ago

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Apr 28, 2025, 4:00 PM EDT - 7 months ago

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Apr 25, 2025, 1:00 PM EDT - 8 months ago

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential

Apr 17, 2025, 5:07 PM EDT - 8 months ago

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Apr 17, 2025, 7:00 AM EDT - 8 months ago

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 8, 2025, 4:00 PM EDT - 8 months ago

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Apr 2, 2025, 7:00 AM EDT - 8 months ago

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 9 months ago

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Mar 17, 2025, 7:00 AM EDT - 9 months ago

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch.

Mar 13, 2025, 4:00 PM EDT - 9 months ago

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch.

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 10 months ago

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Jan 28, 2025, 4:00 PM EST - 11 months ago

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

Jan 22, 2025, 7:00 AM EST - 11 months ago

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation

Jan 9, 2025, 8:44 AM EST - 11 months ago

Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 7:00 AM EST - 11 months ago

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia

Dec 19, 2024, 7:00 AM EST - 1 year ago

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

Dec 9, 2024, 6:00 PM EST - 1 year ago

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

Dec 2, 2024, 7:00 AM EST - 1 year ago

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 7:00 AM EST - 1 year ago

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Nov 20, 2024, 4:00 PM EST - 1 year ago

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Nov 17, 2024, 10:30 AM EST - 1 year ago

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

Oct 21, 2024, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

RonIsWrong
RonIsWrong Dec. 7 at 5:41 AM
$NRIX Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging data from randomized Phase 1b cohorts points to higher ORR and longer progression free survival at the 600 mg recommended Phase 2 dose (RP2D) compared to the 200 mg dose Bexobrutideg was well tolerated with a consistent safety profile between the 600 mg RP2D and the overall study population Phase 2 clinical trial of bexobrutideg (DAYBreak-CLL-201) currently enrolling globally call monday more: https://finance.yahoo.com/news/nurix-therapeutics-presents-data-demonstrating-143000212.html
0 · Reply
justiceforb_85
justiceforb_85 Dec. 7 at 2:15 AM
$NRIX data is good but wondering what the TAM is for relapsed disease? New data out suggesting limited treatment may be feasible in front-line setting.
1 · Reply
oaksapollo
oaksapollo Dec. 6 at 3:26 PM
$NRIX well the update is out, seems pretty much as I expected, but not going to knock anyone’s socks off. I suspect we trade slightly lower Monday? https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-presents-new-data-demonstrating-durable
1 · Reply
LongTrainRunning
LongTrainRunning Dec. 5 at 7:42 PM
$NRIX Looks like the stock is settling in around $18 before ASH. I'm excited to see the ASH data press release, perhaps in a couple hours. Hopefully we start next week off in the 20s. Good luck fellow longs!
1 · Reply
oaksapollo
oaksapollo Dec. 4 at 4:43 PM
$NRIX this is anecdotal but does suggest that maybe bexo data takes time to mature. This patient had a CR after 2 years of treatment!
1 · Reply
oaksapollo
oaksapollo Dec. 4 at 4:28 PM
$NRIX there are not many options trades made for this stock but what little trading does go on seems to indicate the ASH data will be very good. There are bids for even Dec $25 strike calls. We’ll find out Monday.
1 · Reply
degeneratetrader23
degeneratetrader23 Dec. 2 at 4:20 PM
$NRIX whats with the dip?
1 · Reply
Smellmahass
Smellmahass Dec. 1 at 2:32 PM
$NRIX Is this the data on December 8th?
1 · Reply
JFais
JFais Nov. 28 at 10:01 PM
When not seeing much that I like in scans (valuations too rich across sector $XBI) Good reminder to set price alerts for reminders to revisit Most won't get triggered, but the few that do make this practice worth it (by far) Ie. $ARWR at $45, $NRIX at $14, the list goes on..
0 · Reply
JarvisFlow
JarvisFlow Nov. 24 at 6:13 PM
Truist Securities has updated their rating for Nurix Therapeutics ( $NRIX ) to Buy with a price target of 30.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 23 at 3:34 PM
$NRGV 🔥 $NRIX $NRT $NSSC $NTNX
0 · Reply
LongTrainRunning
LongTrainRunning Nov. 21 at 7:24 PM
$NRIX it's nice to see the run-up to ASH finally happening. Now the big unknown is how much room will be left to go up on good news at ASH.
2 · Reply
degeneratetrader23
degeneratetrader23 Nov. 21 at 3:40 PM
$PSNL i am so glad i added to this and $NRIX after lightening up on $ENVX.
1 · Reply
RonIsWrong
RonIsWrong Nov. 21 at 2:34 PM
$NRIX Nurix trims workforce as pivotal trial for lead BTK degrader kicks off https://www.fiercebiotech.com/biotech/nurix-trims-workforce-pivotal-trial-lead-btk-degrader-kicks
1 · Reply
RonIsWrong
RonIsWrong Nov. 20 at 2:55 PM
$NRIX outstanding callout @Wigglyick
2 · Reply
degeneratetrader23
degeneratetrader23 Nov. 20 at 2:34 PM
$NRIX beast mode: ON
0 · Reply
doodoodeity
doodoodeity Nov. 19 at 8:33 PM
$NRIX out at 14.50, nice ~15% gains
1 · Reply
Wigglyick
Wigglyick Nov. 19 at 3:33 PM
$NRIX let’s see if it holds
0 · Reply
DonCorleone77
DonCorleone77 Nov. 19 at 3:27 PM
I'm a bit upset with @Wigglyick. Apparently he called out $NRIX recently as a technical play but he didn't message me directly. And here I thought I was his Godfather 😢
1 · Reply
degeneratetrader23
degeneratetrader23 Nov. 19 at 2:52 PM
$NRIX breakout. Next stop 14.60.
0 · Reply
LongTrainRunning
LongTrainRunning Nov. 19 at 3:47 AM
$NRIX site is showing an incorrect date for the Jefferies Global Healthcare Conference in London. The correct date is Wed Nov 19 at 6 am EST. Their site says Nov 18. You had ONE job! https://wsw.com/webcast/jeff332/nrix/1873651
0 · Reply
doodoodeity
doodoodeity Nov. 18 at 4:33 PM
$NRIX grabbed a few here
0 · Reply